Abdominal wall reconstruction after cytoreduction surgery-hyperthermic intraperitoneal chemotherapy

被引:3
作者
Scholer, Anthony J. [1 ]
Oliver, Joseph B. [1 ]
Rosado, Jesus [1 ]
Patel, Jimmy S. [1 ]
Lynch, Lindsay J. [1 ]
Spiegler, Kevin M. [1 ]
Houck, Karen [2 ]
Chokshi, Ravi J. [3 ]
机构
[1] Rutgers State Univ, New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA
[2] Rutgers State Univ, New Jersey Med Sch, Dept Obstet & Gynecol, Newark, NJ 07103 USA
[3] Rutgers State Univ, New Jersey Med Sch, Sect Surg Oncol, Dept Surg, Newark, NJ 07103 USA
关键词
Abdominal wall reconstruction; Cytoreduction surgery; Hyperthermic intraperitoneal chemotherapy; Outcomes; PERITONEAL CARCINOMATOSIS; PSEUDOMYXOMA PERITONEI; COLORECTAL-CANCER; DISTAL PANCREATECTOMY; OVARIAN-CARCINOMA; OUTCOME DATA; HIPEC; MORBIDITY; ORIGIN; MORTALITY;
D O I
10.1016/j.jss.2017.08.002
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Cytoreduction surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) improve survival and decrease recurrence of peritoneal metastasis in a select population of patients. Abdominal wall resection is often needed to achieve complete CRS and the extent of abdominal wall resection may necessitate abdominal wall reconstruction (AWR). We sought to investigate if postoperative morbidity and mortality was increased in patients who underwent AWR with CRS-HIPEC (AWR group) compared to CRS-HIPEC without AWR (non-AWR group) and to identify if patient, tumor, and operative risk factors were associated with poor outcomes following AWR. We postulate that AWR is a safe and viable treatment option in appropriately selected patients with peritoneal disease. Methods: A retrospective chart review was conducted from 2012 to 2015. Demographics, comorbidities, intraoperative variables, and postoperative outcomes were analyzed and compared between the non-AWR group and the AWR group. Results: A total of 30 patients underwent CRS-HIPEC at our institution; 19 recruited in non-AWR group and 11 in the AWR arm. Median follow-up was 19.1 mo for the non-AWR group and 15.6 mo for AWR. Overall survival and complications were not significantly different between groups. Six patients in the non-AWR group and three patients in AWR group died during the follow-up period (32% versus 27%, P = 0.75). Grade III/IV Clavien-Dindo complications were similar in AWR compared to non-AWR group (64% versus 50%, P = 0.46) however estimated blood loss (1000 mL versus 450 mL, P = 0.01) and operative time (663 min versus 510 min, P = 0.02) were significantly increased in the AWR group. Conclusions: The results of this study demonstrate that AWR is a safe and viable option and can improve wound closure and strength in select patient populations undergoing CRS-HIPEC. AWR is not associated with an increase in mortality or complication rate. Future studies will need larger sample sizes and randomization to identify patient and operative factors that increase morbidity with AWR and identify the ideal timing of AWR. Published by Elsevier Inc.
引用
收藏
页码:266 / 274
页数:9
相关论文
共 50 条
[21]   Early results on the use of biomaterials as adjuvant to abdominal wall closure following cytoreduction and hyperthermic intraperitoneal chemotherapy [J].
Cherif Boutros ;
Ponandai Somasundar ;
N Joseph Espat .
World Journal of Surgical Oncology, 8
[22]   Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Elderly is Safe and Effective [J].
Laks, Shachar ;
Bilik, Alona ;
Schtrechman, Gal ;
Adileh, Mohammad ;
Mor, Eyal ;
Boursi, Ben ;
Halpern, Naama ;
Margalit, Ofer ;
Shacham-Shmueli, Einat ;
Nissan, Aviram ;
Ben-Yaacov, Almog .
JOURNAL OF SURGICAL RESEARCH, 2022, 279 :739-747
[23]   Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review [J].
Auer, Rebecca C. ;
Sivajohanathan, Duvaraga ;
Biagi, Jim ;
Conner, James ;
Kennedy, Erin ;
May, Taymaa .
EUROPEAN JOURNAL OF CANCER, 2020, 127 :76-95
[24]   Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with liver involvement [J].
Berger, Yaniv ;
Aycart, Samantha ;
Tabrizian, Parissa ;
Agmon, Yahel ;
Mandeli, John ;
Heskel, Marina ;
Hiotis, Spiros ;
Sarpel, Umut ;
Labow, Daniel M. .
JOURNAL OF SURGICAL ONCOLOGY, 2016, 113 (04) :432-437
[25]   Hematological toxicities associated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy [J].
Wong, Evelyn Y. T. ;
Tan, Grace H. C. ;
Kumar, Mrinal ;
Teo, Melissa C. C. .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (02) :E38-E46
[26]   Management of Pseudomyxoma Peritonei by Cytoreduction plus HIPEC (Hyperthermic Intraperitoneal Chemotherapy): Results Analysis of a Twelve-year Experience [J].
Vaira, Marco ;
Cioppa, Tommaso ;
De Marco, Giovanni ;
Bing, Camilla ;
D'Amico, Silvia ;
D'Alessandro, Michelina ;
Fiorentini, Giammaria ;
De Simone, Michele .
IN VIVO, 2009, 23 (04) :639-644
[27]   Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Elderly Patients: Complete Cytoreduction Is Feasible and Crucial for Improved Survival Despite High Carcinomatosis Index [J].
Naffouje, Samer A. ;
Salti, George I. .
ANTICANCER RESEARCH, 2018, 38 (01) :441-448
[28]   Complications and Toxicities After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy [J].
Canda, Aras Emre ;
Sokmen, Selman ;
Terzi, Cem ;
Arslan, Cigdem ;
Oztop, Ilhan ;
Karabulut, Bulent ;
Ozzeybek, Deniz ;
Sarioglu, Sulen ;
Fuzun, Mehmet .
ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (04) :1082-1087
[29]   Quality of life in patients with peritoneal surface malignancies after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy [J].
Chia, C. S. ;
Tan, W. J. ;
Wong, J. F. Sze ;
Tan, G. H. Ching ;
Lim, C. ;
Wang, W. ;
Sin, E. I. -L. ;
Tham, C. K. ;
Soo, K. C. ;
Teo, M. C. C. .
EJSO, 2014, 40 (08) :909-916
[30]   Hematological Alterations after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy [J].
Pintado, Maria Consuelo ;
Unzue, Inmaculada Lasa ;
Sanz, Remedios Gomez ;
Alonso, Manuel Diez ;
Ortega, Miguel A. ;
de Mon, Melchor Alvarez ;
Losada, Emilio Nevado ;
Calvo, Alberto Gutierrez .
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (13)